Decoding lung health thru Aerosol Biopsy
by Deton Corp. on August 4th, 2016

​LOS ANGELES – August 4, 2016 – Deton Corp., a medical device company developing innovative products for the diagnosis of lower respiratory infections, has secured $600,000 in an oversubscribed seed financing round. The round was led by a venture fund based in Shanghai and included angel investor participation. “The seed financing comes at a pivotal time for the company, as we accelerate our ongoing efforts in product and market development,” said Patrick Sislian, Ph.D., CEO of Deton Corp. “This financing gets us closer to our goal of becoming the world-leaders in non-invasive sample collection from the lower respiratory tract.”

Deton’s product, the Cough Collector, addresses long standing challenges in the diagnosis of lower respiratory infections.  “The Cough Collector is a great leap building on existing methods for sampling and diagnosis of lower respiratory infections that are dated and often ineffective,” said Antonino Catanzaro, M.D., Chair of Deton’s Medical Advisory Board and Professor of Medicine at the University of California, San Diego. “Deton’s method of sampling aerosols generated by coughing to produce a reliable sample is simple, non-invasive and effective and will lead to faster and more effective treatment of these infections.”

Deton is a participant in the Consortium for Technology and Innovation in Pediatrics (CTIP), a pediatric technology accelerator operated by the Center for Innovation at Children’s Hospital Los Angeles. “We are excited about Deton’s technology and its potential to dramatically improve pediatric patients’ lives,” said Jessica Rousset, Co-Director of CTIP. “We look forward to working more closely with Deton to help bring their product to market.”


About Children's Hospital Los Angeles (CHLA), Center for Innovation (CFI), Consortium for Technology and Innovation in Pediatrics (CTIP)
Children's Hospital Los Angeles has been named the best children’s hospital in California and among the top 10 in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. The Center for Innovation at CHLA raises standards of pediatric care by bringing together clinicians, scientists, engineers, patients and industry leaders to develop, commercialize and implement new devices and medicines specifically for babies and children.  With seed funding from the U.S. Food and Drug Administration (FDA), the CFI oversees the Consortium for Technology and Innovation in Pediatrics (CTIP), an accelerator which engages innovators dedicated to developing unique technology solutions that help pediatric patients. For more information, please visit www.scctip.com.

About Deton Corp.
Deton Corp. is creating products that effectively obtain samples from the lower respiratory tract with a focus on diagnosing infections. Deton’s device non-invasively collects and concentrates cough droplets - the same ones that transmit infections - from the lungs. The result is a concentrated, clean, and easy-to-process sample enabling rapid test results that empower doctors to appropriately prescribe targeted antibiotic therapies when necessary and avoid ineffective treatments that can lead to antibiotic resistance. Deton is headquartered in Pasadena, California (Los Angeles). For more information, please visit www.detoncorp.com


Contact:
Patrick Sislian
310-776-5259
info@detoncorp.com

by Deton Corp. on February 12th, 2016

​Deton Corp. has been awarded a National Institute of Health (NIH) Small Business Innovation Research grant of $225,000 to collect clinical proof of concept data using its third generation Cough Collector prototype.

by Deton Corp. on August 9th, 2012

Deton Corp. presented at the Pasadena Science Collaborative (PBC) yearly company showcase. 

click here for the full article. 

by Deton Corp. on June 5th, 2012

Deton Corp. has been awarded a National Institute of Health (NIH) Advanced Small Business Innovation Research grant of $600,000 for the development of the Cough Collector. The grant is titled "Cough collection as a replacement for sputum samples for diagnosing Tuberculosis."

by Deton Corp. on November 17th, 2011

Deton Corp moved to the Pasadena Bioscience Collaborative (PBC). For more information on the PBC, please visit their website.

by Deton Corp. on October 31st, 2011

"Streamlining Nucleic Acid Sample Prep: Advances in Long-Read Technology, Target Enrichment, and Collection Reshape Operations" Josh P. Roberts - Feature Articles: Jun 1, 2011 (Vol. 31, No. 11). click here

by Deton Corp. on October 31st, 2011


Deton Corp. has received Phase I SBIR funding from the National Science Foundation. The funding will enable a point-of-care device for the diagnosis of lung infections. Phase I work will support the development of the cough collector in this point-of-care device.